ZELLEN, DIE EIN AMYLOIDVORLAUFERPROTEIN UND EIN A-SEKRETASE COEXPRIMIEREN UND DEREN ANWENDUNGEN IN TESTVERFAHREN UND DIAGNOSTIK
    2.
    发明公开
    ZELLEN, DIE EIN AMYLOIDVORLAUFERPROTEIN UND EIN A-SEKRETASE COEXPRIMIEREN UND DEREN ANWENDUNGEN IN TESTVERFAHREN UND DIAGNOSTIK 有权
    细胞一间AMYLOIDVORLAUFERPROTEIN A-分泌共表达及其应用的测试方法和诊断

    公开(公告)号:EP1161524A2

    公开(公告)日:2001-12-12

    申请号:EP00910788.9

    申请日:2000-03-08

    申请人: Fahrenholz, Falk

    IPC分类号: C12N9/64 C07K14/47 A61P25/28

    摘要: The invention relates to a recombinant cell which expresses a substrate protein comprising at least one sequence region of 18 amino acids of the human amyloid precursor protein (APP) or a homologous protein. The sequence region contains the α-secretase cleavage site as well as 6 amino acid rests at the amino terminal and 12 amino acid rests at the carboxy terminal, in relation to the α-secretase cleavage site, and contains either a) a recombinant nucleic acid comprising at least one gene for a protease protein which contains either the sequence region(s), required for proteolytic action, of the disintegrin metalloprotease ADAM 10 obtained from cattle (Bos taurus), humans or another mammal or represents a mutein of a mammalian disintegrin metalloprotease ADAM 10 which has essentially the same enzymatic properties, the gene or genes being controlled by a heterologous promotor; or b) heterologous RNA coding for a substrate protein and a protease protein. The invention also relates to the use of the above cells.

    VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE
    3.
    发明授权
    VARIANTS OF TACE PRO-DOMAIN AS TNF-A INHIBITOR AND THEIR MEDICAL USE 有权
    变体DER TACE PRO-DOMÄNEALS TNF-A-HEMMER UND DEREN MEDIZINISCHE VERWENDUNG

    公开(公告)号:EP2846819B1

    公开(公告)日:2017-05-03

    申请号:EP13729107

    申请日:2013-05-09

    申请人: YEDA RES & DEV

    IPC分类号: A61K38/17 C07K14/00

    摘要: A method of treating an inflammatory disease is disclosed. The method comprises administering to the subject a therapeutically effective amount of a polypeptide comprising a pro-domain of TNF-alpha converting enzyme (TACE), said polypeptide being devoid of a catalytic domain of said TACE, said polypeptide comprising a modification at a site selected from the group consisting of R58, R56 and K57 which renders said polypeptide resistant to furin degradation said polypeptide being capable of downregulating an activity of TACE, thereby treating the inflammatory disease.

    摘要翻译: 公开了一种治疗炎性疾病的方法。 该方法包括向受试者施用治疗有效量的包含TNF-α转化酶(TACE)的前结构域的多肽,所述多肽缺乏所述TACE的催化结构域,所述多肽在选择的位点包含修饰 来自由R58,R56和K57组成的组,其使得所述多肽抵抗弗林蛋白酶降解,所述多肽能够下调TACE的活性,由此治疗炎性疾病。

    ZELLEN, DIE EIN AMYLOIDVORLAUFERPROTEIN UND EIN A-SEKRETASE COEXPRIMIEREN UND DEREN ANWENDUNGEN IN TESTVERFAHREN UND DIAGNOSTIK
    4.
    发明授权
    ZELLEN, DIE EIN AMYLOIDVORLAUFERPROTEIN UND EIN A-SEKRETASE COEXPRIMIEREN UND DEREN ANWENDUNGEN IN TESTVERFAHREN UND DIAGNOSTIK 有权
    细胞一间AMYLOIDVORLAUFERPROTEIN A-分泌共表达及其应用的测试方法和诊断

    公开(公告)号:EP1161524B1

    公开(公告)日:2007-02-21

    申请号:EP00910788.9

    申请日:2000-03-08

    申请人: Fahrenholz, Falk

    IPC分类号: C12N9/64 C07K14/47 A61P25/28

    摘要: The invention relates to a recombinant cell which expresses a substrate protein comprising at least one sequence region of 18 amino acids of the human amyloid precursor protein (APP) or a homologous protein. The sequence region contains the α-secretase cleavage site as well as 6 amino acid rests at the amino terminal and 12 amino acid rests at the carboxy terminal, in relation to the α-secretase cleavage site, and contains either a) a recombinant nucleic acid comprising at least one gene for a protease protein which contains either the sequence region(s), required for proteolytic action, of the disintegrin metalloprotease ADAM 10 obtained from cattle (Bos taurus), humans or another mammal or represents a mutein of a mammalian disintegrin metalloprotease ADAM 10 which has essentially the same enzymatic properties, the gene or genes being controlled by a heterologous promotor; or b) heterologous RNA coding for a substrate protein and a protease protein. The invention also relates to the use of the above cells.